Interview with Aristides Torres Velasco, CEO, Vanquish Mexico
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
The National Institute of Psychiatry Ramón de la Fuente is a decentralized public institution part of the system of National Institutes of Health in Mexico. Founded in 1976 the functions of the Institute are: to conduct scientific research, to instruct qualified personnel to conduct these investigations, to train professionals and technicians in these fields, to treat psychiatric patients and to act as an advisor to other official and private organisms. The Institute participates in the development of health policies by coordinating with institutions at national level with both the government and civil society, by helping in the adoption of new policies in the areas of mental health and substance abuse in its role as member of the National Council against Addictions and organism in charge of mental health in the country. Since 1976 the Institute has been designated as a WHO/PAHO Collaborating Centre and been continuously re-designated every four years until 2015. The Institute possesses three research branches― neuroscience, clinical, epidemiological, and psychosocial research — an education office and an area of clinical services.
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Please can you tell us in your own words how you’ve seen the Mexican pharmaceutical market change over the past five years? Mexico is one of the top ten markets…
You arrived to the position of Boehringer Ingelheim Mexico’s General Director in 2010, what are some of the most exciting milestones and achievements you have presided over during this time?…
Please can you give us a brief rundown of Pierre Fabre’s activities in Mexico since they opened an affiliate here, specifically the company’s milestones and achievements along the way? Pierre…
Since we last spoke to you in 2008, Mexico has undergone a lot of regulatory changes, and we witnessed the rise of Seguro Popular, and the rise of COFEPRIS for…
Grünenthal first started operations in Mexico back in 1998, we then interviewed Mr. Klaus Kuchen in 2005, but we want to know what’s happened since. Please can you give us…
There are about 250 employees and you have regional presence in Latin America. In your view as CEO, can you tell our readers about the biggest growth drivers and challenges…
You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here 11 years ago? The…
Please can you give us a rundown of Shires activities in Mexico in the last four years, and the key achievements and milestones along the way? Shire started operations in…
Please can you give our readers a brief rundown of the major milestones and challenges that you have faced at Octapharma since becoming Managing Director? When Octapharma first came to…
From your perspective in healthcare consultancy at CEGEDIM, what do you think have been the most impactful changes in the Mexican pharmaceutical and healthcare sector over the last few years?…
See our Cookie Privacy Policy Here
